DMYD-B:STO
Diamyd Medical AB
SEK 1.09
arrow_upward
+1.87%(+0.020) 1H
3 Jul, 5:29:51 PTG GMT+2 · SEK
search
Semua simbol
1H
5H
1B
6B
TSS
1T
5T
MAKS
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk DMYD-B...
Buka
SEK 1.07
Tinggi
SEK 1.14
Rendah
SEK 1.05
Permodalan Pasaran
165.11J
Purata volum
939.12K
Volum
769.45K
tgi 52 mgu
SEK 17.88
rdh 52 mgu
SEK 0.90
EPS
-SEK 1.98
Syer tertunggak
134.00J
Bilangan pekerja
44
Buka
SEK 1.07
Tinggi
SEK 1.14
Rendah
SEK 1.05
Permodalan Pasaran
165.11J
Purata volum
939.12K
Volum
769.45K
tgi 52 mgu
SEK 17.88
rdh 52 mgu
SEK 0.90
EPS
-SEK 1.98
Syer tertunggak
134.00J
Bilangan pekerja
44
Cerita berita
Daripada sumber merentas web
AOL.com
·
32 minit lalu
Trump Accounts Default to State Street SPDR Portfolio S&P 500 ETF, Here Are 3 Better ETF Options
TechStock²
·
59 minit lalu
Dow hits record but chips slide in quiet trade ahead of July 4 break
TechStock²
·
1 jam lalu
Marvell (NASDAQ:MRVL) falls as AI data-center surge cools into holiday week
Barron's
·
15 jam lalu
SpaceX Stock Is Joining the Nasdaq 100 Soon. What History Says Happens Next.
Profil
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Perihal Diamyd Medical AB
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut